Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that, on June 22, 2023, Vistagen received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq) indicating that Vistagen has regained full compliance with the minimum $1.00 bid price per share or greater requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Vistagen is now in full compliance with all applicable Nasdaq listing requirements, and Nasdaq considers the matter closed.
Cresco Labs And Columbia Care Terminate Merger, Sale Of Assets To Sean ‘Diddy’ Combs
Cresco Labs (OTCQX: CRLBF) (CSE:CL) (FSE: 6CQ) and Columbia Care (OTCQX: CCHWF) (NEO:CCHW) (CSE:CCHW) announced a mutual agreement, dated July 30, 2023, to amicably terminate the definitive arra
